Dr. Phuong Khanh (P.K.) Morrow Director since 2025 Independent 52 years old Committees: Science and Technology Committee Talent and Compensation Committee Specific Expertise: Dr. Morrow was chosen as a Director because of her deep expertise leading end-to-end clinical development in the field of oncology, with a proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development. Career Highlights: Current Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, where she is responsible for the company's oncology research and development strategy and development portfolio (January 2024 to present) Former Chief Medical Officer, CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and development team members overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular diseases, helped to shepherd the development and subsequent approval of exa-cel, the first CRISPR-edited gene therapy to be approved by the FDA for the treatment of severe sickle cell disease and transfusion-dependent beta-thalassemia (May 2022 to January 2024) Former Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases, Amgen (March 2012 to May 2022) Former Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center (June 2006 to February 2012) Awards: Hematology/Oncology fellowship at the University of Texas MD Anderson Cancer Center Clifton D. Howe (Fellow of the Year) Award American Society of Clinical Oncology Young Investigator Award Lyndon Baines Johnson Chief Fellow Education: Internal medicine residency at Baylor College of Medicine M.D., University of Texas Medical School at Houston